Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/15/2025

Acute Intermittent Porphyria: Clinical Manifestations and Diagnostic Markers

Core Clinical Manifestations

  • The American Association for the Study of Liver Diseases notes that acute intermittent porphyria (AIP) presents primarily with severe abdominal pain and neurological symptoms, representing the most common acute hepatic porphyria in the United States 1, 2
  • Severe abdominal pain is the most prominent symptom, often mimicking acute abdomen or bowel obstruction 1
  • Gastrointestinal symptoms, including nausea, vomiting, constipation, or diarrhea, are common in AIP patients 3
  • Neurological manifestations with peripheral neuropathy and muscle weakness are characteristic of AIP 1, 2
  • The European Association for the Study of the Liver recommends considering AIP in patients with unexplained abdominal pain, neuropsychiatric symptoms, and hyponatremia 3

Diagnostic Biochemical Markers

  • The American Association for Clinical Chemistry states that during an acute attack, urinary porphobilinogen (PBG) is markedly elevated to >10 times the upper limit of normal, which is pathognomonic for acute porphyria 5, 6, 8
  • Urinary delta-aminolevulinic acid (ALA) is also elevated, though less specific than PBG 1, 2
  • The PBG/ALA ratio is approximately 2:1 in AIP patients with normal renal function 5, 6

Demographic and Temporal Patterns

  • The National Institute of Diabetes and Digestive and Kidney Diseases reports that 90% of symptomatic patients are women, with attacks rarely occurring before menarche or after menopause 4
  • Symptoms typically emerge in early adulthood (age range 19-45 years in clinical studies) 7
  • The American College of Medical Genetics and Genomics notes that 90% of patients experience only one or few attacks in their lifetime 4

Precipitating Factors Context

  • The Endocrine Society states that reduced energy intake and fasting are major precipitants of acute attacks 8
  • Hormonal changes related to menstrual cycle, pregnancy (50% experience attacks during pregnancy/puerperium) can trigger symptoms 4
  • Certain medications that induce hepatic cytochrome P450 enzymes (barbiturates, sulfonamides, certain anticonvulsants) can precipitate attacks 8
  • Alcohol, smoking, and stress serve as additional precipitants 4